Back To: Home



June 6-7, 2013
European Lab Automation - Hamburg, Germany

June 12-15, 2013

More Events
Name:
Company:
Email:
 
 
 
PerkinElmer

OGI invests in Rna Diagnostics
April 2012
SHARING OPTIONS:

TORONTO—The Ontario Genomics Institute (OGI) has announced an investment, through its Pre-Commercialization Business Development Fund, in Rna Diagnostics Inc., an early-stage molecular diagnostics company developing assays to assist in chemotherapy management. The funding will help Rna Diagnostics develop and validate its lead product, the RNA Disruption Assay. The assay will aid in determining whether a patient is responding to therapy earlier in the course of treatment than current methods.
 
“One of the key aims of personalized medicine is to provide the right medicine to the right patient at the right time. This assay monitors molecular data from a particular patient to help inform clinical decisions for that patient,” Dr. Mark Poznansky, president and CEO of OGI, said in a statement. “Rna Diagnostics has the potential to create innovative products for the Canadian healthcare system and beyond.”

Back

cISBIO

Tecan


Beckman

Singulex

INDIGO

R&D Systems
CONTACT US
Drug Discovery News
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2013 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.